Fate Therapeutics (FATE) Current Leases (2019 - 2026)

Fate Therapeutics has reported Current Leases for 8 years, with the latest figure at $4.7 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases fell 27.57% year-over-year to $4.7 million; the trailing twelve-month figure through Mar 2026 stood at $4.7 million (down 27.57% YoY), and the FY2025 full-year result was $4.6 million, down 38.48% from the prior year.
• Current Leases for Q1 2026 stood at $4.7 million, up from $4.6 million in the prior quarter.
• The five-year high for Current Leases was $7.4 million in Q4 2024, with the low at $4.6 million in Q4 2025.
• Historically, Current Leases has averaged $5.9 million across 5 years, with a median of $5.8 million in 2022.
• Annual changes were most pronounced in 2022 — Current Leases rose 26.52% — and 2025, when it slumped 38.48%.
• Fate Therapeutics' Current Leases stood at $5.6 million in 2022, then increased by 9.74% to $6.2 million in 2023, then rose by 20.08% to $7.4 million in 2024, then tumbled by 38.48% to $4.6 million in 2025, then rose by 3.9% to $4.7 million in 2026.
• The last three Current Leases figures came in at $4.7 million (Q1 2026), $4.6 million (Q4 2025), and $4.8 million (Q3 2025), per Business Quant data.